RxDoctor Payments Data

Jordan Morgan

Nurse Practitioner · Monroe, LANPI 1366178956

Payments from drug & device makers

$1,284in general payments, 2019–2025

Across 47 payments — averaging $27.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$191
  • UCB, Inc.$145
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$125
  • AstraZeneca$100
  • Boston Scientific$97
  • Curonix LLC$81
  • plus $545 from 18 others

What the payments were for

  • Food & beverage$1,284100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,284 in reported general payments places this provider in the 70th percentile of 969 nurse practitioner providers in Louisiana.

See all nurse practitioner providers in Louisiana

Medicare billing

Part B allowed, 2024
$11,391
Medicare patients
66
Services billed
902

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Gamunex-CImmune Globul G/Gly/Iga Avg 4633$161,394
BriviactBrivaracetam20$24,116
Lacosamide44$2,025
Levetiracetam40$700
Gabapentin31$567
Carbidopa-LevodopaCarbidopa/Levodopa39$398
Carbidopa-Levodopa ErCarbidopa/Levodopa12$214
Levothyroxine Sodium12$137
Lamotrigine27$136
Donepezil Hcl19$117
Atorvastatin Calcium12$107
Topiramate16$98
Pantoprazole Sodium13$72
Amlodipine Besylate12$42

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
UCB, Inc.Briviact$145$24,11620 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 969 nurse practitioner providers in Louisiana.

Other nurse practitioner in Monroe

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →